• 1
    Stehlik J, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: Twenty-seventh official adult heart transplant report–2010. J Heart Lung Transplant 2010;29:10891103.
  • 2
    Ballantyne CM, Podet EJ, Patsch WP, et al.Effects of cyclosporine therapy on plasma lipoprotein levels. Jama 1989;262:5356.
  • 3
    Ettinger WH, Klinefelter HF, Kwiterovitch PO. Effect of short-term, low-dose corticosteroids on plasma lipoprotein lipids. Atherosclerosis 1987;63:167172.
  • 4
    Lee KF, Pierce JD, Hess ML, Hastillo AK, Wechsler AS, Guerraty AJ. Cardiac transplantation with corticosteroid-free immunosuppression: Long-term results. Ann Thorac Surg 1991;52:211217; discussion 8.
  • 5
    Hricik DE, Mayes JT, Schulak JA. Independent effects of cyclosporine and prednisone on posttransplant hypercholesterolemia. Am J Kidney Dis 1991;18:353358.
  • 6
    Yuan X, Paez-Cortez J, Schmitt-Knosalla I, et al. A novel role of CD4 Th17 cells in mediating cardiac allograft rejection and vasculopathy. J Exp Med 2008;205:31333144.
  • 7
    Gross MD, Bielinski SJ, Suarez-Lopez JR, et al. Circulating soluble intercellular adhesion molecule 1 and subclinical atherosclerosis: The Coronary Artery Risk Development in Young Adults Study. Clin Chem 2012;58:411420.
  • 8
    Wu WK, Llewellyn OP, Bates DO, Nicholson LB, Dick AD. IL-10 regulation of macrophage VEGF production is dependent on macrophage polarisation and hypoxia. Immunobiology 2010;215:796803.
  • 9
    Reinders ME, Fang JC, Wong W, Ganz P, Briscoe DM. Expression patterns of vascular endothelial growth factor in human cardiac allografts: Association with rejection. Transplantation 2003;76:224230.
  • 10
    Wong BW, Rahmani M, Luo Z, et al. Vascular endothelial growth factor increases human cardiac microvascular endothelial cell permeability to low-density lipoproteins. J Heart Lung Transplant 2009;28:950957.
  • 11
    Yu H, Clarke MC, Figg N, Littlewood TD, Bennett MR. Smooth muscle cell apoptosis promotes vessel remodeling and repair via activation of cell migration, proliferation, and collagen synthesis. Arterioscler Thromb Vasc Biol 2011;31:24022409.
  • 12
    Clarke MC, Talib S, Figg NL, Bennett MR. Vascular smooth muscle cell apoptosis induces interleukin-1-directed inflammation: Effects of hyperlipidemia-mediated inhibition of phagocytosis. Circ Res 2010;106:363372.
  • 13
    Diaz JA, Booth AJ, Lu G, Wood SC, Pinsky DJ, Bishop DK. Critical role for IL-6 in hypertrophy and fibrosis in chronic cardiac allograft rejection. Am J Transplant 2009;9:17731783.
  • 14
    Booth AJ, Csencsits-Smith K, Wood SC, Lu G, Lipson KE, Bishop DK. Connective tissue growth factor promotes fibrosis downstream of TGFbeta and IL-6 in chronic cardiac allograft rejection. Am J Transplant 2010;10:220230.
  • 15
    Raisanen-Sokolowski A, Tilly-Kiesi M, Ustinov J, et al. Hyperlipidemia accelerates allograft arteriosclerosis (chronic rejection) in the rat. Arterioscler Thromb 1994;14:20322042.
  • 16
    Alonso DR, Starek PK, Minick CR. Studies on the pathogenesis of atheroarteriosclerosis induced in rabbit cardiac allografts by the synergy of graft rejection and hypercholesterolemia. Am J Pathol 1977;87:415442.
  • 17
    Tanaka H, Sukhova GK, Libby P. Interaction of the allogeneic state and hypercholesterolemia in arterial lesion formation in experimental cardiac allografts. Arterioscler Thromb 1994;14:734745.
  • 18
    Eich D, Thompson JA, Ko DJ, et al. Hypercholesterolemia in long-term survivors of heart transplantation: An early marker of accelerated coronary artery disease. J Heart Lung Transplant 1991;10:4549.
  • 19
    Park JW, Merz M, Braun P, Vermeltfoort M. Lipid disorder and transplant coronary artery disease in long-term survivors of heart transplantation. J Heart Lung Transplant 1996;15:572579.
  • 20
    Dimeny E. Metabolic factors and outcome of organ transplantation. Scand J Urol Nephrol Suppl 1994;159:174.
  • 21
    Dimeny E, Tufveson G, Lithell H, Larsson E, Siegbahn A, Fellstrom B. The influence of pretransplant lipoprotein abnormalities on the early results of renal transplantation. Eur J Clin Invest 1993;23:572579.
  • 22
    Dimeny E, Wahlberg J, Lithell H, Fellstrom B. Hyperlipidaemia in renal transplantation—Risk factor for long-term graft outcome. Eur J Clin Invest. 1995;25:574583.
  • 23
    Isoniemi H, Nurminen M, Tikkanen MJ, et al. Risk factors predicting chronic rejection of renal allografts. Transplantation 1994;57:6872.
  • 24
    Tanabe S, Ueda M, Han YS, et al. Presence of oxidized LDL in transplant arteriosclerotic lesions obtained from renal transplant recipients with hypercholesterolemia. Transplant Proc 1998;30:116118.
  • 25
    Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med. 1995;333:621627.
  • 26
    Kobashigawa JA, Moriguchi JD, Laks H, et al. Ten-year follow-up of a randomized trial of pravastatin in heart transplant patients. J Heart Lung Transplant 2005;24:17361740.
  • 27
    Wenke K, Meiser B, Thiery J, Reichart B. Impact of simvastatin therapy after heart transplantation an 11-year prospective evaluation. Herz . 2005;30:431432.
  • 28
    Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 2002;346:539540.
  • 29
    Bruckert E, Hayem G, Dejager S, Yau C, Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients—The PRIMO study. Cardiovasc Drugs Ther 2005;19:403414.
  • 30
    East C, Alivizatos PA, Grundy SM, Jones PH, Farmer JA. Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation. N Engl J Med 1988;318:4748.
  • 31
    Golomb BA, Evans MA. Statin adverse effects: A review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs 2008;8:373418.
  • 32
    Bergman AJ, Burke J, Larson P, et al. Interaction of single-dose ezetimibe and steady-state cyclosporine in renal transplant patients. J Clin Pharmacol 2006;46:328336.
  • 33
    Yamazaki M, Suzuki H, Hanano M, Tokui T, Komai T, Sugiyama Y. Na(+)-independent multispecific anion transporter mediates active transport of pravastatin into rat liver. Am J Physiol 1993;264:G36G44.
  • 34
    Ballantyne CM, Corsini A, Davidson MH, et al. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med 2003;163:553564.
  • 35
    Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003;289:16811690.
  • 36
    Surette ME, Whelan J, Broughton KS, Kinsella JE. Evidence for mechanisms of the hypotriglyceridemic effect of n-3 polyunsaturated fatty acids. Biochim Biophys Acta 1992;1126:199205.
  • 37
    Davidson MH. Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids. Am J Cardiol 2006;98:27i–33i.
  • 38
    Jailal I, Devaraj S, Huet BA, Traber M. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico. Lancet 1999;354:447455.
  • 39
    Barbir M, Hunt B, Kushwaha S, et al. Maxepa versus bezafibrate in hyperlipidemic cardiac transplant recipients. Am J Cardiol 1992;70:15961601.
  • 40
    Celik S, Doesch A, Erbel C, et al. Beneficial effect of omega-3 fatty acids on sirolimus- or everolimus-induced hypertriglyceridemia in heart transplant recipients. Transplantation 2008;86:245250.
  • 41
    Holm T, Andreassen AK, Aukrust P, et al. Omega-3 fatty acids improve blood pressure control and preserve renal function in hypertensive heart transplant recipients. Eur Heart J 2001;22:428436.
  • 42
    Andreassen AK, Hartmann A, Offstad J, Geiran O, Kvernebo K, Simonsen S. Hypertension prophylaxis with omega-3 fatty acids in heart transplant recipients. J Am Coll Cardiol 1997;29:13241331.
  • 43
    Lim AK, Manley KJ, Roberts MA, Fraenkel MB. Fish oil treatment for kidney transplant recipients: A meta-analysis of randomized controlled trials. Transplantation 2007;83:831838.
  • 44
    Yessoufou A, Ple A, Moutairou K, Hichami A, Khan NA. Docosahexaenoic acid reduces suppressive and migratory functions of CD4+CD25+ regulatory T-cells. J Lipid Res 2009;50:23772388.
  • 45
    Fowler KH, Chapkin RS, McMurray DN. Effects of purified dietary n-3 ethyl esters on murine T lymphocyte function. J Immunol 1993;151:51865197.
  • 46
    Wang J, Ma H, Li Q, Li Y, Li J. Long-term n-3 polyunsaturated fatty acids administration ameliorates arteriosclerosis by modulating T-cell activity in a rat model of small intestine transplantation. Clin Chim Acta 2007;381:124130.
  • 47
    Iwami D, Zhang Q, Aramaki O, Nonomura K, Shirasugi N, Niimi M. Purified eicosapentaenoic acid induces prolonged survival of cardiac allografts and generates regulatory T cells. Am J Transplant 2009;9:12941307.
  • 48
    Kun Z, Haiyun Z, Meng W, Li N, Li Y, Li J. Dietary omega-3 polyunsaturated fatty acids can inhibit expression of granzyme B, perforin, and cation-independent mannose 6-phosphate/insulin-like growth factor receptor in rat model of small bowel transplant chronic rejection. JPEN J Parenter Enteral Nutr 2008;32:1217.
  • 49
    Ogita K, Suita S, Taguchi T, et al. Effects of omega-3 fatty acids in rat allogenic small intestinal transplantation. Pediatr Surg Int 2003;19:157161.
  • 50
    Schrepf R, Limmert T, Claus Weber P, Theisen K, Sellmayer A. Immediate effects of n-3 fatty acid infusion on the induction of sustained ventricular tachycardia. Lancet 2004;363:14411442.
  • 51
    Mozaffarian D, Geelen A, Brouwer IA, Geleijnse JM, Zock PL, Katan MB. Effect of fish oil on heart rate in humans: A meta-analysis of randomized controlled trials. Circulation 2005;112:19451952.
  • 52
    Christensen JH, Christensen MS, Dyerberg J, Schmidt EB. Heart rate variability and fatty acid content of blood cell membranes: A dose-response study with n-3 fatty acids. Am J Clin Nutr 1999;70:331337.
  • 53
    Leaf A, Xiao YF, Kang JX, Billman GE. Membrane effects of the n-3 fish oil fatty acids, which prevent fatal ventricular arrhythmias. J Membr Biol 2005;206:129139.
  • 54
    Harris WS, Gonzales M, Laney N, Sastre A, Borkon AM. Effects of omega-3 fatty acids on heart rate in cardiac transplant recipients. Am J Cardiol 2006;98:13931395.
  • 55
    Frost L, Vestergaard P. n-3 Fatty acids consumed from fish and risk of atrial fibrillation or flutter: the Danish Diet, Cancer, and Health Study. Am J Clin Nutr 2005;81:5054.
  • 56
    Virtanen JK, Mursu J, Voutilainen S, Tuomainen TP. Serum long-chain n-3 polyunsaturated fatty acids and risk of hospital diagnosis of atrial fibrillation in men. Circulation 2009;120:23152321.
  • 57
    Saravanan P, Davidson NC, Schmidt EB, Calder PC. Cardiovascular effects of marine omega-3 fatty acids. Lancet 2010;376:540550.
  • 58
    Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): A subgroup analysis of a randomised controlled trial. Lancet 2008;372:817821.
  • 59
    Kashani A, Sallam T, Bheemreddy S, Mann DL, Wang Y, Foody JM. Review of side-effect profile of combination ezetimibe and statin therapy in randomized clinical trials. Am J Cardiol 2008;101:16061613.
  • 60
    Pearson TA, Denke MA, McBride PE, Battisti WP, Brady WE, Palmisano J. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: The ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin Proc 2005;80:587595.
  • 61
    Farnier M, Volpe M, Massaad R, Davies MJ, Allen C. Effect of co-administering ezetimibe with on-going simvastatin treatment on LDL-C goal attainment in hypercholesterolemic patients with coronary heart disease. Int J Cardiol 2005;102:327332.
  • 62
    Brohet C, Banai S, Alings AM, Massaad R, Davies MJ, Allen C. LDL-C goal attainment with the addition of ezetimibe to ongoing simvastatin treatment in coronary heart disease patients with hypercholesterolemia. Curr Med Res Opin 2005;21:571578.
  • 63
    Mikhailidis DP, Sibbring GC, Ballantyne CM, Davies GM, Catapano AL. Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Curr Med Res Opin 2007;23:20092026.
  • 64
    Koshman SL, Lalonde LD, Burton I, Tymchak WJ, Pearson GJ. Supratherapeutic response to ezetimibe administered with cyclosporine. Ann Pharmacother 2005;39:15611565.
  • 65
    Bergman AJ, Burke J, Larson P, et al. Effects of ezetimibe on cyclosporine pharmacokinetics in healthy subjects. J Clin Pharmacol 2006;46:321327.
  • 66
    Shaw SM, Chaggar P, Ritchie J, et al. The efficacy and tolerability of ezetimibe in cardiac transplant recipients taking cyclosporin. Transplantation 2009;87:771775.
  • 67
    Quarta CC, Potena L, Grigioni F, et al. Safety and efficacy of ezetimibe with low doses of simvastatin in heart transplant recipients. J Heart Lung Transplant 2008;27:685688.
  • 68
    Konstandin MH, Blessing E, Doesch A, et al. Ezetimibe effectively lowers LDL-cholesterol in cardiac allograft recipients on stable statin therapy. Clin Transplant 2008;22:639644.
  • 69
    Peto R, Emberson J, Landray M, et al. Analyses of cancer data from three ezetimibe trials. N Engl J Med 2008;359:13571366.
  • 70
    Halleck M, Davis HR, Kirschmeier P, et al. An assessment of the carcinogenic potential of ezetimibe using nonclinical data in a weight-of-evidence approach. Toxicology 2009;258:116130.
  • 71
    Zambrana JL, Velasco F, Castro P, et al. Comparison of bezafibrate versus lovastatin for lowering plasma insulin, fibrinogen, and plasminogen activator inhibitor-1 concentrations in hyperlipemic heart transplant patients. Am J Cardiol 1997;80:836840.
  • 72
    Hunt BJ, Segal H, Yacoub M. Haemostatic changes after heart transplantation and their relationship to accelerated coronary sclerosis. Transplant Proc 1991;23:12331235.
  • 73
    Meade TW, Mellows S, Brozovic M, et al. Haemostatic function and ischaemic heart disease: Principal results of the Northwick Park Heart Study. Lancet 1986;2:533537.
  • 74
    Davies MJ, Thomas A. Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death. N Engl J Med 1984;310:11371140.
  • 75
    Pflugfelder PW, Huff M, Oskalns R, Rudas L, Kostuk WJ. Cholesterol-lowering therapy after heart transplantation: A 12-month randomized trial. J Heart Lung Transplant 1995;14:613622.
  • 76
    Peters JR, Kubo SH, Olivari MT, Knutson KR, Hunninghake DB. Treatment of hyperlipidemia in heart transplant recipients with gemfibrozil +/- lovastatin. Am J Cardiol 1993;71:14851488.
  • 77
    Omar MA, Wilson JP, Cox TS. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother 2001;35:10961107.
  • 78
    Shek A, Ferrill MJ. Statin-fibrate combination therapy. Ann Pharmacother 2001;35:908917.
  • 79
    Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: A double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004;110:35123517.
  • 80
    Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: Long-term benefit with niacin. J Am Coll Cardiol 1986;8:12451255.
  • 81
    Florentin M, Liberopoulos EN, Kei A, Mikhailidis DP, Elisaf MS. Pleiotropic effects of nicotinic acid: Beyond high density lipoprotein cholesterol elevation. Curr Vasc Pharmacol 2011;9:385400.
  • 82
    Rosenson RS. Antiatherothrombotic effects of nicotinic acid. Atherosclerosis 2003;171:8796.
  • 83
    Tavintharan S, Sivakumar M, Lim SC, Sum CF. Niacin affects cell adhesion molecules and plasminogen activator inhibitor-1 in HepG2 cells. Clin Chim Acta 2007;376:4144.
  • 84
    Wu BJ, Yan L, Charlton F, Witting P, Barter PJ, Rye KA. Evidence that niacin inhibits acute vascular inflammation and improves endothelial dysfunction independent of changes in plasma lipids. Arterioscler Thromb Vasc Biol 2010;30:968975.
  • 85
    Uzark K, Crowley D, Callow L, Bove E. Hypercholesterolemia after cardiac transplantation in children. Am J Cardiol 1990;66:13851387.
  • 86
    Henkin Y, Oberman A, Hurst DC, Segrest JP. Niacin revisited: Clinical observations on an important but underutilized drug. Am J Med 1991;91:239246.
  • 87
    Tobert JA. Efficacy and long-term adverse effect pattern of lovastatin. Am J Cardiol 1988;62:28J34J.
  • 88
    Lal SM, Hewett JE, Petroski GF, Van Stone JC, Ross G, Jr. Effects of nicotinic acid and lovastatin in renal transplant patients: A prospective, randomized, open-labeled crossover trial. Am J Kidney Dis 1995;25:616622.
  • 89
    Jensen RA, Lal SM, Diaz-Arias A, James-Kracke M, Van Stone JC, Ross G, Jr. Does cholestyramine interfere with cyclosporine absorption? A prospective study in renal transplant patients. Asaio J. 1995;41:M704M706.
  • 90
    Van Leeuwen PA, Boermeester MA, Houdijk AP, et al. Pretreatment with enteral cholestyramine prevents suppression of the cellular immune system after partial hepatectomy. Ann Surg 1995;221:282290.
  • 91
    Andrade SE, Walker AM, Gottlieb LK, et al. Discontinuation of antihyperlipidemic drugs—Do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med 1995;332:11251131.
  • 92
    Guida B, Perrino NR, Laccetti R, et al. Role of dietary intervention and nutritional follow-up in heart transplant recipients. Clin Transplant 2009;23:101107.
  • 93
    Miettinen TA, Puska P, Gylling H, Vanhanen H, Vartiainen E. Reduction of serum cholesterol with sitostanol-ester margarine in a mildly hypercholesterolemic population. N Engl J Med 1995;333:13081312.
  • 94
    Vorlat A, Conraads VM, Vrints CJ. Regular use of margarine-containing stanol/sterol esters reduces total and low-density lipoprotein (LDL) cholesterol and allows reduction of statin therapy after cardiac transplantation: Preliminary observations. J Heart Lung Transplant 2003;22:10591062.
  • 95
    Marchioli R, Barzi F, Bomba E, et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: Time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI)-Prevenzione. Circulation 2002;105:18971903.
  • 96
    Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): A randomised, double-blind, placebo-controlled trial. Lancet 2008;372:12231230.
  • 97
    Crespo-Leiro MG, Paniagua MJ, Marzoa R, et al. The efficacy and safety of ezetimibe for treatment of dyslipidemia after heart transplantation. Transplant Proc 2008;40:30603062.
  • 98
    Guisado Rasco A, Lage Galle E, Sobrino Marquez JM, et al. Safety and efficacy of ezetimibe in a sample of cardiac transplant patients. Transplant Proc 2008;40:30583059.
  • 99
    Le VV, Racine N, Pelletier GB, Carrier M, Cossette M, White M. Impact of ezetimibe on cholesterol subfractions in dyslipidemic cardiac transplant recipients receiving statin therapy. Clin Transplant 2009;23:249255.
  • 100
    Moro J, Almenar L, Martinez-Dolz L, et al. Ezetimibe in heart transplantation: Initial experience. Transplant Proc 2007;39:23892392.
  • 101
    Patel AR, Ambrose MS, Duffy GA, Cote H, DeNofrio D. Treatment of hypercholesterolemia with ezetimibe in cardiac transplant recipients. J Heart Lung Transplant 2007;26:281284.
  • 102
    Baigent C, Landry M. Study of Heart and Renal Protection (SHARP). Kidney Int Suppl 2003:S207S210.
  • 103
    Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:12371245.
  • 104
    Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial. Lancet 2005;366:18491861.
  • 105
    Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999;341:410418.
  • 106
    Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: The Bezafibrate Infarction Prevention (BIP) study. Circulation 2010;102:21217.
  • 107
    The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. Jama 1984;251:365374.
  • 108
    Turpeinen O, Karvonen MJ, Pekkarinen M, Miettinen M, Elosuo R, Paavilainen E. Dietary prevention of coronary heart disease: The Finnish Mental Hospital Study. Int J Epidemiol 1979;8:99118.